Soligenix Launches Public Offering to Advance Rare Disease Treatment Research and Development

Soligenix Launches Public Offering to Fuel R&D in Rare Disease Treatments

Soligenix, Inc., a biopharmaceutical company dedicated to developing therapies for rare diseases, announces a public offering priced at $1.35 per share. The offering includes 5,555,560 shares of common stock alongside warrants to purchase an equal number of shares. This initiative is projected to generate approximately $7.5 million in gross proceeds, which will be instrumental in advancing the company's research and development pipeline, as well as supporting its commercialization efforts. The deal is anticipated to close around September 29, 2025, contingent upon customary closing conditions.

The proceeds from this offering are earmarked for multiple strategic purposes, including enhancing research and development capabilities, bolstering commercialization activities, and contributing to general working capital needs. The commitment to rare disease treatment underlines Soligenix's focus on addressing unmet medical needs, which is critical in a market often overlooked by larger pharmaceutical companies. The company has also announced amendments to existing warrants from earlier offerings to align their exercise price with the new offering, indicating a strategic move to consolidate financial terms for investors.

The offering is facilitated by A.G.P./Alliance Global Partners, who serves as the sole placement agent. To ensure compliance with regulatory requirements, the securities are offered under a registration statement filed with the Securities and Exchange Commission (SEC). This proactive approach highlights Soligenix's commitment to transparency and regulatory adherence, reinforcing investor confidence. The preliminary prospectus is already accessible to interested parties, with a final prospectus expected to be available shortly.

In addition to the funding announcement, Soligenix continues to focus on its innovative pipeline aimed at treating rare diseases. The company remains steadfast in its mission to develop effective therapies, which is crucial in a field often characterized by limited treatment options. By securing additional funding, Soligenix positions itself to advance its clinical trials and potentially bring new therapies to market.

Overall, Soligenix's public offering marks a significant step in its ongoing efforts to address the challenges of rare diseases, demonstrating its dedication to improving patient outcomes through innovative biopharmaceutical solutions.